A non-interventional observational study in adults assessing the safety and tolerability of AVANZ® in case of concomitant specific immunotherapy (SCIT/AIT/SLIT)

Completed

• Conditions: J30.1; J30.3; Allergic rhinitis due to pollen; Other allergic rhinitis

• Registration Number: DRKS00005030
• Lead Sponsor: ALK-Abelló Arzneimittel GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-05-28
• Study Completion: 2014-04-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 311

Inclusion Criteria

Routine treatment with subcutaneous specific immunotherapy (AVANZ®) and concomitant treatment with further specific immunotherapy

Exclusion Criteria

Contraindications of specific immunotherapy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency and type of adverse events recorded by the physician during administration of subcutaneous injections and in patient diaries coded acc. to MedDRA for the first 4 months of treatment

Secondary Outcome Measures

Name	Time	Method
Global assessment of tolerability by patient and physician after 4 months of treatment